Doug Janzen Appointed to AbCellera's Board of Directors
Vancouver, Canada (August 9, 2014) - AbCellera is pleased to announce the appointment of Doug Janzen to Chair of its board of directors.
Doug brings over 20 years of experience in life sciences with leadership experience in corporate finance, business development, and management. Over his 9 year tenure at Cardiome Pharma (NASDAQ: CRME) Doug held a series of positions including Chief Financial Officer (2003 – 2005), President and Chief Business Officer (2005-2009), and President and Chief Executive Officer (2009-2012). During this time he raised over $300 million from investors, completed over $1 billion in licensing deals, and lead a partnership with Merck to bring Cardiome’s lead product, Brinavess, through to clinical approval and marketing in Europe.
Doug is currently Co-Founder and Managing Director of NorthView Ventures, President and CEO of Aequus Pharmaceuticals, and serves on the Boards of Aequus Pharmaceuticals, Alabaster Technologies, Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies. Prior to Cardiome Doug was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences and has completed over $1B in equity financing for Canadian biotech companies.
Doug remains a prominent figure in the BC and Canadian biotechnology and has held previous positions as Chair of LifeSciences BC, Director with Biotech Canada, and winner of Business in Vancouver’s “Top 40 Under 40 Award”.